Literature DB >> 10854213

Glomerular expression of type IV collagen chains in normal and X-linked Alport syndrome kidneys.

L Heidet1, Y Cai, L Guicharnaud, C Antignac, M C Gubler.   

Abstract

Alport syndrome is an inherited nephropathy characterized by alterations of the glomerular basement membrane because of mutations in type IV collagen genes. COL4A5 mutations, causing X-linked Alport syndrome, frequently result in the loss of the alpha5 chains of type IV collagen in basement membranes. This is associated with the absence of the alpha3(IV) and alpha4(IV) chains and increased amounts of alpha1(IV) and alpha2(IV) in glomerular basement membranes. The mechanisms resulting in such a configuration are still controversial and are of fundamental importance for understanding the pathology of the disease and for considering gene therapy. In this article we studied, for the first time, type IV collagen expression in kidneys from X-linked Alport syndrome patients, using in situ hybridization and immunohistochemistry. We show that, independent of the type of mutation and of the level of COL4A5 transcription, both COL4A3 and COL4A4 genes are actively transcribed in podocytes. Moreover, using immunofluorescence amplification, we were able to demonstrate that the alpha3 chain of type IV collagen was present in the podocytes of all patients. Finally, the alpha1(IV) chain, which accumulates within glomerular basement membranes, was found to be synthesized by mesangial/endothelial cells. These results strongly suggest that, contrary to what has been found in dogs affected with X-linked Alport syndrome, there is no transcriptional co-regulation of COL4A3, COL4A4, and COL4A5 genes in humans, and that the absence of alpha3(IV) to alpha5(IV) in glomerular basement membranes in the patients results from events downstream of transcription, RNA processing, and protein synthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854213      PMCID: PMC1850092          DOI: 10.1016/S0002-9440(10)65063-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  58 in total

1.  Complete primary structure of the human type IV collagen alpha 4(IV) chain. Comparison with structure and expression of the other alpha (IV) chains.

Authors:  A Leinonen; M Mariyama; T Mochizuki; K Tryggvason; S T Reeders
Journal:  J Biol Chem       Date:  1994-10-21       Impact factor: 5.157

2.  Seminiferous tubule basement membrane. Composition and organization of type IV collagen chains, and the linkage of alpha3(IV) and alpha5(IV) chains.

Authors:  T Z Kahsai; G C Enders; S Gunwar; C Brunmark; J Wieslander; R Kalluri; J Zhou; M E Noelken; B G Hudson
Journal:  J Biol Chem       Date:  1997-07-04       Impact factor: 5.157

3.  Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.

Authors:  R Kalluri; C F Shield; P Todd; B G Hudson; E G Neilson
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

4.  The structural genes for alpha 1 and alpha 2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have an overlapping promoter region.

Authors:  R Soininen; M Huotari; S L Hostikka; D J Prockop; K Tryggvason
Journal:  J Biol Chem       Date:  1988-11-25       Impact factor: 5.157

5.  Colocalization of the genes for the alpha 3(IV) and alpha 4(IV) chains of type IV collagen to chromosome 2 bands q35-q37.

Authors:  M Mariyama; K Zheng; T L Yang-Feng; S T Reeders
Journal:  Genomics       Date:  1992-07       Impact factor: 5.736

6.  Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.

Authors:  K Yoshioka; S Hino; T Takemura; S Maki; J Wieslander; Y Takekoshi; H Makino; M Kagawa; Y Sado; C E Kashtan
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Expression of type IV collagen alpha 3 and alpha 4 chain mRNA in X-linked Alport syndrome.

Authors:  K Nakanishi; N Yoskikawa; K Iijima; H Nakamura
Journal:  J Am Soc Nephrol       Date:  1996-06       Impact factor: 10.121

8.  Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution.

Authors:  M C Gubler; B Knebelmann; A Beziau; M Broyer; Y Pirson; F Haddoum; M M Kleppel; C Antignac
Journal:  Kidney Int       Date:  1995-04       Impact factor: 10.612

9.  X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene.

Authors:  A Renieri; M Bruttini; L Galli; P Zanelli; T Neri; S Rossetti; A Turco; N Heiskari; J Zhou; R Gusmano; L Massella; G Banfi; F Scolari; A Sessa; G Rizzoni; K Tryggvason; P F Pignatti; M Savi; A Ballabio; M De Marchi
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

10.  In situ hybridization reveals temporal and spatial changes in cellular expression of mRNA for a laminin receptor, laminin, and basement membrane (type IV) collagen in the developing kidney.

Authors:  G W Laurie; S Horikoshi; P D Killen; B Segui-Real; Y Yamada
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

View more
  29 in total

1.  Learning cell biology as a team: a project-based approach to upper-division cell biology.

Authors:  Robin Wright; James Boggs
Journal:  Cell Biol Educ       Date:  2002

2.  Glomerular basement membrane and related glomerular disease.

Authors:  Ying Maggie Chen; Jeffrey H Miner
Journal:  Transl Res       Date:  2012-04-10       Impact factor: 7.012

3.  Protective effects of leukemia inhibitory factor against oxidative stress during high glucose-induced apoptosis in podocytes.

Authors:  Jing Xu; Zhigui Li; Pengjuan Xu; Zhuo Yang
Journal:  Cell Stress Chaperones       Date:  2012-01-22       Impact factor: 3.667

4.  Cellular origins of type IV collagen networks in developing glomeruli.

Authors:  Dale R Abrahamson; Billy G Hudson; Larysa Stroganova; Dorin-Bogdan Borza; Patricia L St John
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

5.  Stem cell therapy for Alport syndrome: the hope beyond the hype.

Authors:  Oliver Gross; Dorin-Bogdan Borza; Hans-Joachim Anders; Christoph Licht; Manfred Weber; Stephan Segerer; Roser Torra; Marie-Claire Gubler; Laurence Heidet; Scott Harvey; Dominic Cosgrove; George Lees; Clifford Kashtan; Martin Gregory; Judy Savige; Jie Ding; Paul Thorner; Dale R Abrahamson; Corinne Antignac; Karl Tryggvason; Billy Hudson; Jeffrey H Miner
Journal:  Nephrol Dial Transplant       Date:  2008-12-25       Impact factor: 5.992

6.  Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease.

Authors:  Hikaru Sugimoto; Thomas M Mundel; Malin Sund; Liang Xie; Dominic Cosgrove; Raghu Kalluri
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

7.  VP23R of infectious spleen and kidney necrosis virus mediates formation of virus-mock basement membrane to provide attaching sites for lymphatic endothelial cells.

Authors:  Xiaopeng Xu; Shaoping Weng; Ting Lin; Junliang Tang; Lichao Huang; Jing Wang; Xiaoqiang Yu; Ling Lu; Zhijian Huang; Jianguo He
Journal:  J Virol       Date:  2010-09-01       Impact factor: 5.103

Review 8.  Basement membranes in the cornea and other organs that commonly develop fibrosis.

Authors:  Paramananda Saikia; Carla S Medeiros; Shanmugapriya Thangavadivel; Steven E Wilson
Journal:  Cell Tissue Res       Date:  2018-10-03       Impact factor: 5.249

9.  A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3-/- Alport mice.

Authors:  Laurence Heidet; Dorin-Bogdan Borza; Mélanie Jouin; Mireille Sich; Marie-Geneviève Mattei; Yoshikazu Sado; Billy G Hudson; Nicholas Hastie; Corinne Antignac; Marie-Claire Gubler
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome.

Authors:  Laura Massella; Concetta Gangemi; Kostas Giannakakis; Antonella Crisafi; Tullio Faraggiana; Chiara Fallerini; Alessandra Renieri; Andrea Onetti Muda; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.